

## Supporting Information

### *Streptococcus pneumoniae* Sialidase SpNanB-Catalyzed One-Pot Multienzyme (OPME) Synthesis of 2,7-Anhydro-Sialic acids as Selective Sialidase Inhibitors

An Xiao,<sup>1</sup> Teri J. Slack,<sup>1</sup> Yanhong Li,<sup>1</sup> Dashuang Shi,<sup>2</sup> Hai Yu,<sup>1</sup> Wanqing Li,<sup>1</sup> Yang Liu,<sup>2,†</sup> and Xi Chen<sup>1,\*</sup>

<sup>1</sup> Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, United States.

<sup>2</sup> Children's National Medical Center, 111 Michigan Ave, NW, Washington DC 20012, United States.

† Present Address: Division of Immunotherapy, Institute of Human Virology, University of Maryland, Baltimore, MD 21201, United States

\*Corresponding author: xiichen@ucdavis.edu


### Table of Contents

<b>Table S1.</b> Substrate specificity of SpNanB.....	S2
<b>Figure S1.</b> Substrate specificity study of SpNanB.....	S3
<b>Figure S2.</b> Mass spectrometry result of the reaction mixture of Neu5Ac7N <sub>3</sub> α2–3Galβ <sub>p</sub> NP treated with SpNanB.....	S3
<b>Table S2.</b> Percentage inhibition (%) of 2,7-anhydro-sialic acids ( <b>1–4</b> ) against bacterial and human sialidases.....	S4
<sup>1</sup> H and <sup>13</sup> C NMR spectra of 2,7-anhydro-Neu5Ac ( <b>1</b> ).....	S5
<sup>1</sup> H and <sup>13</sup> C NMR spectra of 2,7-anhydro-Neu5TFA ( <b>2</b> ).....	S6
<sup>1</sup> H and <sup>13</sup> C NMR spectra of 2,7-anhydro-Neu ( <b>3</b> ).....	S7
<sup>1</sup> H and <sup>13</sup> C NMR spectra of 2,7-anhydro-Neu5Cyclohexyl ( <b>4</b> ).....	S8


**Table S1.** Substrate specificity of SpNanB. Acceptable substrate is shown with “+” and nonacceptable substrate is shown with “-”.

Substrate	Sia $\alpha$ 2-3Gal $\beta$ pNP	Sia $\alpha$ 2-6Gal $\beta$ pNP
Neu5Ac-R	+	-
Neu5AcF-R	+	-
Neu5AcOMe-R	+	-
Neu5AcN <sub>3</sub> -R	+	-
Neu5Ac9F-R	+	-
Neu5Ac9OMe-R	+	-
Neu5Ac9deoxy-R	+	-
Neu5Ac9N <sub>3</sub> -R	+	-
Neu5Ac9NAc-R	+	-
Neu5Ac7F-R	+	-
Neu5Ac7OMe-R	+	-
Neu5Ac7deoxy-R	+	-
Neu5Ac7N <sub>3</sub> -R	+	-
Neu5Gc-R	+	-
Neu5Gc9F-R	+	-
Neu5Gc9OMe-R	+	-
Neu5Gc9deoxy-R	+	-
Neu5Gc9N <sub>3</sub> -R	+	-
Kdn-R	-	-
Kdn5F-R	-	-
Kdn5N <sub>3</sub> -R	-	-
Kdn5deoxy-R	-	-
Kdn5OMe-R	-	-
Kdn9F-R	-	-
Kdn9OMe-R	-	-
Kdn9deoxy-R	-	-
Kdn9N <sub>3</sub> -R	-	-
Kdn7F-R	-	-
Kdn7OMe-R	-	-
Kdn7deoxy-R	-	-
Kdn7N <sub>3</sub> -R	-	-

**Figure S1.** Substrate specificity study of SpNanB using Sia $\alpha$ 2–3Gal $\beta$ pNP (white columns) or Sia $\alpha$ 2–6Gal $\beta$ pNP (black columns) as substrates.




**Figure S2.** Mass spectrometry result of the reaction mixture of Neu5Ac7N $\alpha$ 2–3Gal $\beta$ pNP treated with SpNanB.




**Table S2.** Percentage inhibition (%) of 2,7-anhydro-sialic acids (**1–4**) (1 mM of each inhibitor was used) against bacterial and human sialidases. Neu5Ac2en was used as a control. Those with more than 50% inhibition are highlighted in bold.

Sialidases	Inhibitors				
	Neu5Ac2en	(1)	(2)	(3)	(4)
SpNanA	<b>98.9</b> ± 1.8	36.4 ± 0.1	<b>83.8</b> ± 0.3	19.3 ± 4.2	<b>61.2</b> ± 0.6
SpNanB	26.1 ± 1.0	30.0 ± 1.7	<b>68.2</b> ± 2.6	11.7 ± 2.6	<b>86.6</b> ± 0.3
SpNanC	9.0 ± 3.5	3.0 ± 1.9	4.4 ± 2.0	14.9 ± 3.0	<b>94.2</b> ± 0.1
AuSialidase	<b>99.6</b> ± 0.6	49.4 ± 1.3	<b>85.1</b> ± 0.3	1.3 ± 2.2	16.8 ± 2.4
CpNanI	<b>93.3</b> ± 3.8	26.7 ± 3.7	44.1 ± 1.0	10.1 ± 5.7	13.6 ± 0.1
VcSialidase	<b>98.8</b> ± 0.1	22.7 ± 1.2	<b>62.1</b> ± 0.6	1.3 ± 2.0	1.2 ± 0.7
PmST1	15.8 ± 0.1	10.2 ± 2.8	11.0 ± 2.7	13.8 ± 3.3	12.3 ± 1.9
BiNanH2	<b>95.3</b> ± 0.2	6.6 ± 1.8	3.8 ± 2.6	3.2 ± 3.2	1.2 ± 0.9
hNEU2	<b>99.8</b> ± 0.2	4.6 ± 1.1	2.5 ± 2.1	1.4 ± 2.4	3.6 ± 0.1




$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 2,7-anhydro-Neu5Ac (**1**)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 2,7-anhydro-Neu5TFA (2)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 2,7-anhydro-Neu (**3**)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 2,7-anhydro-Neu5Cyclohexyl (**4**)

